

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

**INSIDE INFORMATION ANNOUNCEMENT
NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED
CONDITIONAL MARKETING APPROVAL FOR DISITAMAB VEDOTIN
(BRAND NAME: 爱地希®) TO TREAT LOCALLY ADVANCED OR
METASTATIC GASTRIC CANCER (GASTROESOPHAGEAL JUNCTION
(GEJ) CARCINOMA) IN CHINA
AND
RESUMPTION OF TRADING**

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥（煙台）股份有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to announce that on June 9, 2021, disitamab vedotin (RC48, Brand Name: 爱地希®), the novel anti-HER2 antibody-drug conjugate (ADC) independently developed in-house by the Company, has been granted conditional marketing approval by the National Medical Products Administration of the People’s Republic of China for the treatment of locally advanced or metastatic gastric cancer (gastroesophageal junction (GEJ) carcinoma) (GC).

The disitamab vedotin (RC48, Brand Name: 爱地希®) is the second approved marketing product following the approval granted for telitacicept in March this year in China and is also a significant accomplishment of the Group. It signifies the Group’s achievements in the field of oncology. It also demonstrates the Group’s ability to develop biologic drugs and reflects the Group’s strong in-house research and development capabilities, especially the ability to develop ADC products.

ABOUT DISITAMAB VEDOTIN (RC48, Brand Name: 爱地希®)

Disitamab vedotin (RC48, Brand Name: 爱地希®) is an anti-HER2 antibody drug conjugate targeting prevalent cancers with significant unmet medical needs, and it is the first domestically developed ADC in China to have entered clinical development. We are implementing a differentiated development and commercial strategy for disitamab vedotin, targeting prevalent HER2 expressing indications that are currently underserved, including HER2 expressing and HER2 low-expressing breast cancer (BC), HER2 expressing gastric cancer (GC) and urothelial carcinoma (UC), and other HER2 expressing cancer indications. These therapeutic areas represent a less crowded but underserved field for HER2 targeted therapies, and a broad addressable patient population for disitamab vedotin.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that the disitamab vedotin will ultimately be successfully marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

RESUMPTION OF TRADING

At the request of the Company, trading in shares on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) was halted with effect from 3:14 p.m. on June 9, 2021 pending publication of this announcement. An application has been made by the Company to the Stock Exchange for resumption of trading in shares on the Stock Exchange with effect from 9:00 a.m. on June 10, 2021.

By order of the Board
RemeGen Co., Ltd.
Mr. Wang Weidong
Chairman and executive director

Yantai, The People’s Republic of China
June 9, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.

* *For identification purposes only*